Testicular Cancer Clinical Trial
Official title:
The Relationship of Ochratoxin A to Upper Tract TCC Malignancies, Testicular Cancer, and Renal Cell Cancer
This pilot study will explore the relationship of Ochratoxin A (OTA) levels in patients with upper tract transitional cell (TCC), renal cell, and testicular cancers by measuring levels of OTA in serum and tumor samples. Dietary exposure will also be analyzed.
Ochratoxin A (OTA, a ubiquitous mycotoxin) is a common food contaminant that enters the food
chain from plants such as cereals. OTA can be inhaled or ingested and livestock and humans
feeding on OTA contaminated food have been found to have detectable levels of this chemical
in their sera, liver, and kidneys.
There is risk for occupational and environmental exposure to OTA. Thus, exposure to this
mycotoxin may be a poorly recognized problem in our society. OTA has been classified as a
group 2b possible carcinogen. Exposure to OTA has been implicated in teratogenesis (fetal
malformation), nephrotoxicity, gonadotoxicity and carcinogenesis. The mechanisms for these
effects of OTA have not been fully explained. There is an increasing incidence of testis
cancer in Western societies combined with the increasing OTA exposures being reported. As
well as studying the relationship of OTA to TCC initially, we also plan to examine a
possible relationship between OTA and testicular cancer as well as renal cell carcinoma
(RCC). To date, very little research into the effects of mycotoxins in humans has been
performed. We plan to apply proven techniques of serum analysis using:
1. ELISA or Enzyme Linked Immuno-absorbent Assay which is used to measure the presence of
an antibody or antigen in the bloodstream
2. Immunohistochemistry (pathological analysis from resected tumors)
3. High -pressure liquid chromatography (HPLC) of tumor tissue to investigate the role of
OTA in human genitourinary cancers. A group of subjects without cancer will be used as
a control group.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00772694 -
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
|
Phase 2 | |
Completed |
NCT00705094 -
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
|
N/A | |
Terminated |
NCT00531687 -
Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
|
Phase 2 | |
Terminated |
NCT00820287 -
Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk
|
N/A | |
Active, not recruiting |
NCT03142802 -
Low-Dose CT - Stage I Testicular Cancer
|
N/A | |
Recruiting |
NCT03232541 -
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
|
N/A | |
Completed |
NCT03557177 -
Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer
|
||
Active, not recruiting |
NCT01783145 -
Shared Care Follow-up After Chemotherapy for Testicular Cancer
|
||
Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
Completed |
NCT02573584 -
Vascular Fingerprint Validation Study
|
||
Recruiting |
NCT05670938 -
Follow-up After Surgery for Testicular Cancer
|
||
Recruiting |
NCT02994758 -
Development of Diagnostics and Treatment of Urological Cancers
|
N/A | |
Completed |
NCT02991209 -
Study of Testosterone vs Placebo in Testicular Cancer Survivors
|
Phase 2/Phase 3 | |
Completed |
NCT02602041 -
Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study
|
||
Completed |
NCT02092740 -
REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg
|
N/A | |
Completed |
NCT01482741 -
Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging
|
N/A | |
Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 | |
Completed |
NCT01242631 -
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
|
Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Completed |
NCT00183820 -
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
|
Phase 2 |